Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 9Terminated 6Recruiting 5Unknown 3Withdrawn 1Suspended 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 5Thoracic 4Head & Neck 4Genitourinary 4Other solid neoplasm 2Tumor-Agnostic 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Gastrointestinal 1

Conditions

Recurrence 1Fallopian Tube Neoplasms 1

Interventions

pembrolizumab 45Paclitaxel 45Carboplatin 39Magnetic Resonance Spectroscopy 28olaparib 27Specimen Handling 26Cisplatin 24Bevacizumab 20Nivolumab 18Taxes 17Biopsy 16Gemcitabine 13Cyclophosphamide 13durvalumab 12Immunoglobulin G 11Doxorubicin 11Disulfides 11Surveys and Questionnaires 10niraparib 9liposomal doxorubicin 9dostarlimab 9Radiotherapy 8Brachytherapy 8lenvatinib 7fludarabine 7atezolizumab 7Letrozole 7Docetaxel 7cediranib 6Platinum 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Interleukin-2 × Gynecologic × Clear all
NCT01883297 2024-09-05

"Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

University Health Network, Toronto

Phase 1 Active not recruiting
3 enrolled
Gynecologic

Fallopian Tube Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡